

Appln No.: 09/944,326
Amendment Dated: October 19, 2007
Reply to Office Action of September 4, 2007

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A pharmaceutical composition, comprising an antisense oligonucleotide which inhibits expression of TRPM-2 by tumor cells, and a pharmaceutically acceptable carrier suitable for human administration for providing the oligonucleotide to a mammalian subject to reduce expression of TRPM-2 wherein the antisense oligonucleotide comprises the sequence given by SEQ ID No. 4 and wherein the composition further comprises a second antisense oligodeoxynucleotide which inhibits expression of an anti-apoptotic protein other than TRPM-2.
- 2 - 12. (canceled)
13. (currently amended) The composition of claim 1 ~~12~~, wherein the second antisense oligodeoxynucleotide is antisense Bcl-2 oligodeoxynucleotide.
14. (canceled)
15. (previously presented) The composition of claim 13, wherein the antisense oligonucleotide having the sequence given by SEQ ID No. 4 is modified to increase the stability of the ODN *in vivo*.
- 16-22. (canceled)
23. (previously presented) The pharmaceutical composition of claim 1, wherein the pharmaceutically acceptable carrier is a lipid carrier.

Appln No.: 09/944,326

Amendment Dated: October 19, 2007

Reply to Office Action of September 4, 2007

24. (currently amended) A pharmaceutical composition, comprising an antisense oligonucleotide which inhibits expression of TRPM-2 by tumor cells, and a pharmaceutically acceptable carrier suitable for human administration for providing the oligonucleotide to a mammalian subject to reduce expression of TRPM-2 wherein the antisense oligonucleotide comprises the sequence given by SEQ ID No. 4, wherein the composition further comprises ~~The pharmaceutical composition according to claim 1,~~ further comprising an additional antisense oligonucleotide that binds specifically to a sequence other than TRPM-2 mRNA.
25. (original) The pharmaceutical composition according to claim 24, wherein the additional antisense oligonucleotide binds specifically to a sequence selected from among Bcl-2, Bcl-1x and c-myc.
26. (original) The pharmaceutical composition according to claim 25, wherein the additional oligonucleotide consists of the sequence set forth in the Seq. ID No. 13.
- 27-29. (canceled)
30. (previously presented) The pharmaceutical composition of claim 1, where the oligonucleotide consists of the sequence given by SEQ ID No. 4.